Published in Semin Thromb Hemost on January 01, 2000
PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model. Blood (2010) 1.61
Structural and functional insights into sulfated galactans: a systematic review. Glycoconj J (2009) 0.87
Guideline adherence for antithrombotic therapy in acute coronary syndrome: an overview in Dutch hospitals. Neth Heart J (2010) 0.82
Anti-Inflammatory Effects of Heparin and Its Derivatives: A Systematic Review. Adv Pharmacol Sci (2015) 0.79
Influence of low molecular weight heparin (certoparin) and unfractionated heparin on the release of cytokines from human leukocytes. Inflammation (2001) 0.78
Microarray method for the rapid detection of glycosaminoglycan-protein interactions. Methods Mol Biol (2012) 0.77
The effect of a low molecular weight heparin on coagulation parameters in healthy cats. Can J Vet Res (2009) 0.75
Heparin: Effects upon the Glycocalyx and Endothelial Cells. J Extra Corpor Technol (2017) 0.75
Unexpected and striking effect of heparin-free dialysis on cytokine release. Int Urol Nephrol (2017) 0.75
The antiphospholipid-thrombosis syndromes. Fact, fiction, confusion, and controversy. Am J Clin Pathol (1993) 1.93
Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemost (1999) 1.42
Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. Semin Thromb Hemost (1978) 1.22
Antithrombin III(AT-III) as a diagnostic aid in disseminated intravascular coagulation. Thromb Res (1977) 1.13
A new two-stage functional assay for antithrombin-III (heparin cofactor): clinical and laboratory evaluation. Thromb Res (1976) 0.92
Circadian relationship of serum uric acid and nitric oxide. JAMA (2000) 0.92
Hemostasis defects associated with cardiac surgery, prosthetic devices, and other extracorporeal circuits. Semin Thromb Hemost (1985) 0.92
Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol (1999) 0.91
Hemodynamic and fibrinolytic consequences of intermittent pneumatic compression: preliminary results. J Trauma (1996) 0.91
Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy. Med Clin North Am (1998) 0.91
Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. Clin Chem (1998) 0.88
Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial. Int Angiol (1996) 0.86
A consensus conference on complex biologics and low molecular weight heparins. Int Angiol (2010) 0.86
Hydroxyethyl starch versus albumin in cardiopulmonary bypass prime solutions. Ann Thorac Surg (1983) 0.85
Pharmacology of the low-molecular-weight heparins. Semin Thromb Hemost (1996) 0.84
Histiocytic medullary reticulosis in two Chinese women. West J Med (1974) 0.84
Antithrombin III patterns in disseminated intravascular coagulation. Am J Clin Pathol (1980) 0.84
Hereditary and acquired thrombophilia. Part I. Preface. Semin Thromb Hemost (1999) 0.84
Soluble P-selectin in human plasma: effect of anticoagulant matrix and its levels in patients with cardiovascular disorders. Clin Appl Thromb Hemost (2000) 0.84
Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders. Expert Opin Investig Drugs (2001) 0.83
Fibrinolytic activity in acute myocardial infarction. Am J Clin Pathol (1972) 0.83
Antithrombin agents as anticoagulants and antithrombotics: implications in drug development. Semin Hematol (1999) 0.83
In-vivo platelet inhibition by piracetam. Lancet (1979) 0.83
Laboratory modalities for assessing hemostasis during cardiopulmonary bypass. Semin Thromb Hemost (1976) 0.82
Bleeding times, platelet adhesion, and aspirin. Am J Clin Pathol (1976) 0.82
Alterations of hemostasis associated with cardiopulmonary bypass: pathophysiology, prevention, diagnosis, and management. Semin Thromb Hemost (1976) 0.82
Coagulation laboratory testing in patients treated with argatroban. Semin Thromb Hemost (1999) 0.82
Anemia of malignancy. Hematol Oncol Clin North Am (1996) 0.81
Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome. Clin Appl Thromb Hemost (1999) 0.81
Thrombotic thrombocytopenic purpura. An extended editorial. Semin Thromb Hemost (1979) 0.81
Heparins in the new millennium: will unfractionated heparin survive? Epilogue. Semin Thromb Hemost (2000) 0.80
Tissue factor pathway inhibitor release induced by defibrotide and heparins. Clin Appl Thromb Hemost (2001) 0.80
Clinical use of intrapulmonary heparin. Semin Thromb Hemost (1985) 0.80
Blood levels of nitric oxide, C-reactive protein, and tumor necrosis factor-alpha are upregulated in patients with malignancy-associated hypercoagulable state: pathophysiologic implications. Clin Appl Thromb Hemost (2004) 0.80
Laboratory evaluation of antithrombin III: a critical overview of currently available methods for antithrombin III measurements. Semin Thromb Hemost (1982) 0.80
Comparative tissue factor pathway inhibitor release potential of heparins. Clin Appl Thromb Hemost (2005) 0.80
Antithrombin III and factor VIII in patients with neoplasms. Am J Clin Pathol (1978) 0.79
In vitro coagulant and amidolytic methods for evaluating the activity of heparin and a low molecular weight derivative (PK 10169). Semin Thromb Hemost (1985) 0.79
Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments. Semin Thromb Hemost (1985) 0.79
Contaminants in heparins continue to be unfolded. Int Angiol (2008) 0.79
Comparative pharmacologic profile of a glycosaminoglycan mixture, Sulodexide, and a chemically modified heparin derivative, Suleparoide. Semin Thromb Hemost (1993) 0.79
Validity of serine protease inhibition tests in the evaluation and monitoring of the effect of heparin and its fractions. Semin Thromb Hemost (1985) 0.79
Disseminated intravascular coagulation and related syndromes: etiology, pathophysiology, diagnosis, and management. Am J Hematol (1978) 0.79
Clinical relevance of antithrombin III. Semin Thromb Hemost (1982) 0.79
Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulation. Semin Thromb Hemost (1999) 0.78
In vitro protamine neutralization profiles of heparins differing in source and molecular weight. Semin Thromb Hemost (1989) 0.78
Day-night variations in blood levels of nitric oxide, T-TFPI, and E-selectin. Clin Appl Thromb Hemost (2001) 0.78
Pharmacokinetics of low molecular weight heparins in animal models. Semin Thromb Hemost (1999) 0.78
Anticoagulant and antiprotease effects of a novel heparinlike compound from shrimp (Penaeus brasiliensis) and its neutralization by heparinase I. Clin Appl Thromb Hemost (2001) 0.78
The clinical significance of fibrinogen degradation products. Semin Thromb Hemost (1982) 0.78
Hemostatic defects induced by cardiopulmonary bypass. Vasc Surg (1976) 0.77
Prothrombin complex concentrate: use in controlling the hemorrhagic diathesis of chronic liver disease. Am J Dig Dis (1975) 0.77
Deep vein thrombosis. Diagnosis and management. Med Clin North Am (1994) 0.77
Global and molecular hemostatic markers in acute myeloid leukemia. Am J Clin Pathol (1990) 0.76
Malaria in drug addicts. JAMA (1971) 0.76
Studies on the profibrinolytic actions of heparin and its fractions. Semin Thromb Hemost (1985) 0.76
Treatment of hereditary and acquired thrombophilic disorders. Semin Thromb Hemost (1999) 0.76
The rheological changes after cesarean section: The influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clin Hemorheol Microcirc (2007) 0.76
Acquired defects of fibrinolysis associated with thrombosis. Semin Thromb Hemost (1999) 0.76
Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: some objective considerations. Semin Thromb Hemost (1989) 0.76
Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro--modulatory action of glycosaminoglycans. Thromb Res (1994) 0.76
Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88). Clin Appl Thromb Hemost (2001) 0.76
A supersulfated low-molecular-weight heparin (IK-SSH) increases plasma levels of free and total tissue factor pathway inhibitor after intravenous and subcutaneous administration in humans. Blood Coagul Fibrinolysis (1998) 0.76
Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin Appl Thromb Hemost (1999) 0.76
Malaria transmission among narcotic addicts. A report of ten cases and review of the literature. Calif Med (1971) 0.75
Ecarin clotting time is sensitive to heparinoids: comparison of two different techniques. Clin Appl Thromb Hemost (2001) 0.75
Antiphospholipid antibodies in coronary artery disease: a review. Semin Thromb Hemost (1994) 0.75
Letter: Prothrombin complex concentrates and chronic liver disease. Thromb Res (1975) 0.75
The effect of pinealectomy and environmental lighting on the gonadal, thyroid, and total body weight of female Long-Evans rats. Experientia (1969) 0.75
Molecular markers of hemostatic activation. Implications in the diagnosis of thrombosis, vascular, and cardiovascular disorders. Clin Lab Med (1995) 0.75
Evidence for a new activation phase clotting abnormality in a patient with the Hughes-Stoven syndrome. Beitr Pathol (1974) 0.75
Usefulness of fibrinopeptide A generation tests in experimental and clinical studies with low molecular weight heparin fractions. Semin Thromb Hemost (1985) 0.75
Daunomycin and fibrinolysis. Thromb Res (1976) 0.75
Pharmacological modulation of fibrinolysis by antithrombotic and cardiovascular drugs. Prog Cardiovasc Dis (1992) 0.75
Preliminary report on the use of CCNU (NSC-79037), adriamycin (NSC-123127), and hexamethylmelamine (NSC-13875) in carcinoma of the lung. Cancer Treat Rep (1976) 0.75
Postoperative monitoring of low molecular weight heparin prophylaxis in high-risk patients. Semin Thromb Hemost (1993) 0.75
Defibrotide mediated inhibition of serotonin, endothelin-I, thromboxane, and serum induced contraction of canine femoral and pulmonary arterial rings. Thromb Res (1996) 0.75
In vivo study of bleeding and antithrombotic effects of low molecular weight heparin ML-009723. Semin Thromb Hemost (1993) 0.75
Disseminated intravascular coagulation and blood component therapy. Transfusion (1976) 0.75
Letter: Prothrombin complex concentrates and chronic liver disease. Thromb Diath Haemorrh (1975) 0.75
Surgical hemostasis with a factor XL-containing concentrate. JAMA (1974) 0.75
Thrombogenesis in myocardial infarction and related syndromes: the role of molecular markers in diagnosis and management. Clin Appl Thromb Hemost (1999) 0.75
Pharmacologic profiling of defibrotide in experimental models. Semin Thromb Hemost (1988) 0.75
Alterations of hemostasis associated with cardiopulmonary bypass. Thromb Res (1976) 0.75
Antithrombin agents: the new class of anticoagulant and antithrombotic drugs. Clin Appl Thromb Hemost (1999) 0.75
Molecular markers of hemostatic activation in atherosclerosis: a new concept in diagnostic profiling of endogenous pathophysiologic transition. Semin Thromb Hemost (1986) 0.75
Fibrinolytic potential in polycythemia rubra vera. Beitr Pathol (1974) 0.75
Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization. J Card Surg (2005) 0.75
Laboratory studies on the intravenous and subcutaneous administration of PK 10169 in man. Haemostasis (1986) 0.75
Soluble adhesion molecules in the HIT syndrome: pathophysiologic role and therapeutic modulation. Clin Appl Thromb Hemost (1999) 0.75
A comparison of the pharmacokinetic and pharmacodynamic profiles of Clexane and Lovenox in dogs. Semin Thromb Hemost (1993) 0.75
Adriamycin and fibrinolysis. Thromb Res (1976) 0.75
Antithrombin agents as anticoagulants and antithrombotics. Implications in drug development. Med Clin North Am (1998) 0.75
Evaluation of hematologic alterations associated with daily administration of low molecular weight heparin (Mono-Embolex) for a 12-week period. Semin Thromb Hemost (1993) 0.75
Clinical laboratory monitoring of a synthetic antithrombin agent, argatroban, using high performance liquid chromatography and functional methods. Int Angiol (1999) 0.75
Preclinical differentiation of low molecular weight heparins. Semin Thromb Hemost (1999) 0.75
Pharmacologic profile of sulfamino-galactosaminoglycans. Semin Thromb Hemost (1991) 0.75
Current perspectives on low molecular weight heparins. Semin Thromb Hemost (1993) 0.75